ZA201407799B - Imidazothiadiazole an imidazopyrazine derivatives as protease activated receptor 2(par4) inhibitors for treating platelet aggregation - Google Patents

Imidazothiadiazole an imidazopyrazine derivatives as protease activated receptor 2(par4) inhibitors for treating platelet aggregation

Info

Publication number
ZA201407799B
ZA201407799B ZA2014/07799A ZA201407799A ZA201407799B ZA 201407799 B ZA201407799 B ZA 201407799B ZA 2014/07799 A ZA2014/07799 A ZA 2014/07799A ZA 201407799 A ZA201407799 A ZA 201407799A ZA 201407799 B ZA201407799 B ZA 201407799B
Authority
ZA
South Africa
Prior art keywords
imidazothiadiazole
par4
inhibitors
platelet aggregation
activated receptor
Prior art date
Application number
ZA2014/07799A
Other languages
English (en)
Inventor
Michael R Lawrence
Brad D Maxwell
Eldon Scott Priestley
Laurence Dube
Daniel H Deon
Roger Remillard
Michael M Miller
Pancras C Wong
Shoshana L Posy
Julia Guy
Marc Gagnon
Edward H Ruediger
Jacques Banville
Original Assignee
Bristol Myers Squibb Co
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Univ Montreal filed Critical Bristol Myers Squibb Co
Publication of ZA201407799B publication Critical patent/ZA201407799B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2014/07799A 2012-04-26 2014-10-24 Imidazothiadiazole an imidazopyrazine derivatives as protease activated receptor 2(par4) inhibitors for treating platelet aggregation ZA201407799B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261638577P 2012-04-26 2012-04-26
US201361787680P 2013-03-15 2013-03-15
PCT/US2013/037956 WO2013163279A1 (en) 2012-04-26 2013-04-24 Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation

Publications (1)

Publication Number Publication Date
ZA201407799B true ZA201407799B (en) 2015-12-23

Family

ID=48407806

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/07799A ZA201407799B (en) 2012-04-26 2014-10-24 Imidazothiadiazole an imidazopyrazine derivatives as protease activated receptor 2(par4) inhibitors for treating platelet aggregation

Country Status (36)

Country Link
US (6) US9688695B2 (en:Method)
EP (3) EP3632919B1 (en:Method)
JP (1) JP6073464B2 (en:Method)
KR (3) KR102176379B1 (en:Method)
CN (2) CN104583218B (en:Method)
AR (1) AR090834A1 (en:Method)
AU (1) AU2013251632B2 (en:Method)
BR (1) BR112014026643B1 (en:Method)
CA (1) CA2871650C (en:Method)
CL (1) CL2014002915A1 (en:Method)
CO (1) CO7160040A2 (en:Method)
CY (2) CY1119466T1 (en:Method)
DK (3) DK3632919T3 (en:Method)
EA (1) EA026724B1 (en:Method)
ES (3) ES2935173T3 (en:Method)
FI (1) FI3632919T3 (en:Method)
HR (3) HRP20171453T1 (en:Method)
HU (3) HUE060743T2 (en:Method)
IL (1) IL235246B (en:Method)
LT (2) LT2841437T (en:Method)
MX (1) MX354175B (en:Method)
MY (1) MY175061A (en:Method)
NZ (1) NZ631027A (en:Method)
PE (1) PE20142285A1 (en:Method)
PH (1) PH12014502173B1 (en:Method)
PL (3) PL3243826T3 (en:Method)
PT (3) PT3243826T (en:Method)
RS (3) RS56395B1 (en:Method)
SG (1) SG11201406757SA (en:Method)
SI (3) SI3243826T1 (en:Method)
SM (3) SMT202300004T1 (en:Method)
TN (1) TN2014000436A1 (en:Method)
TW (1) TWI572605B (en:Method)
UY (1) UY34763A (en:Method)
WO (1) WO2013163279A1 (en:Method)
ZA (1) ZA201407799B (en:Method)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163244A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
JP6101343B2 (ja) 2012-04-26 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピリダジン誘導体
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016138199A1 (en) 2015-02-26 2016-09-01 Bristol-Myers Squibb Company Benzothiazole and benzothiophne compounds
ES2929208T3 (es) 2015-02-26 2022-11-25 Univ Montreal Compuestos de imidazotiadiazol como inhibidores de PAR4
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2017066863A1 (en) 2015-10-19 2017-04-27 Universite De Montreal Heterocyclic compounds as inhibitors of platelet aggregation
US9963466B2 (en) 2016-03-07 2018-05-08 Vanderbilt University Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists
US20190119300A1 (en) * 2016-04-18 2019-04-25 Vanderbilt University Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists
KR102460385B1 (ko) * 2016-07-14 2022-10-27 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물
KR102492715B1 (ko) 2016-07-14 2023-01-26 브리스톨-마이어스 스큅 컴퍼니 모노시클릭 헤테로아릴 치환된 화합물
CN109689649B (zh) * 2016-07-14 2022-07-19 百时美施贵宝公司 经二环杂芳基取代的化合物
EP3484894B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
CN108239083B (zh) 2016-12-26 2021-08-17 阿里根公司 芳香烃受体调节剂
CN111587249A (zh) 2017-11-20 2020-08-25 阿里根公司 吲哚化合物及其用途
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019149205A1 (zh) * 2018-01-31 2019-08-08 江苏恒瑞医药股份有限公司 苯并杂芳基类衍生物、其制备方法及其在医药上的应用
CN110218218B (zh) * 2018-03-01 2022-04-08 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN110272436A (zh) * 2018-03-14 2019-09-24 中国药科大学 氘代的咪唑并噻二唑衍生物及其医药用途
WO2019218957A1 (zh) * 2018-05-16 2019-11-21 深圳信立泰药业股份有限公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
CN112074521B (zh) * 2018-05-16 2022-08-09 深圳信立泰药业股份有限公司 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物
CN110627817B (zh) * 2018-06-25 2022-03-29 中国药科大学 咪唑并环类par4拮抗剂及其医药用途
KR20210052435A (ko) * 2018-08-30 2021-05-10 니혼 메디피직스 가부시키가이샤 방사성 이미다조티아디아졸 유도체 화합물
WO2020106695A1 (en) 2018-11-19 2020-05-28 Ariagen, Inc. Methods of treating cancer
IL284222B2 (en) 2018-12-21 2025-09-01 Bristol Myers Squibb Co Macrocrystalline forms of the PAR4 inhibitor
CN111349105B (zh) * 2018-12-24 2023-04-07 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN111362970A (zh) * 2018-12-25 2020-07-03 天津药物研究院有限公司 苯并呋喃类衍生物及其制备方法和用途
AU2020258394A1 (en) 2019-04-15 2021-10-28 Ariagen, Inc. Chiral indole compounds and their use
EP3782702A1 (en) * 2019-08-21 2021-02-24 AC BioScience SA Compounds and use thereof for the treatment of infectious diseases and cancer
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN113150005B (zh) * 2021-04-09 2022-08-30 中国药科大学 喹喔啉类化合物、制备方法及其在医药上的应用
US12077607B2 (en) 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2823686A1 (de) * 1978-05-31 1979-12-06 Bayer Ag Imidazo eckige klammer auf 2.1-b eckige klammer zu eckige klammer auf 1.3.4 eckige klammer zu -thiadiazole
DE3020421A1 (de) 1980-05-29 1981-12-10 Bayer Ag, 5090 Leverkusen Imidazoazolalkensaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
US4444770A (en) 1980-05-29 1984-04-24 Bayer Aktiengesellschaft New imidazoazole-alkenoic acid amide compounds, intermediate products for their production, their production, and their medicinal use
DE3446778A1 (de) 1984-12-21 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
GB8901423D0 (en) 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2060138A1 (en) 1991-01-29 1992-07-30 Youichi Shiokawa New use of the adenosine antagonist
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
ATE413403T1 (de) 1999-10-08 2008-11-15 Gruenenthal Gmbh Bicyclische imidazo-5-yl-aminderivate
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
DE10019714A1 (de) 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
US6387942B2 (en) 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
EP1442028A4 (en) 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
CA2364985A1 (en) 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
WO2004063159A1 (ja) 2003-01-10 2004-07-29 Idemitsu Kosan Co., Ltd. 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
CA2527903A1 (en) 2003-06-13 2004-12-23 Aegera Therapeutics, Inc. Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxides and sulfones
JP2006527209A (ja) 2003-06-13 2006-11-30 アエジェラ・セラピューティクス・インコーポレーテッド アシル化及び非−アシル化イミダゾ［２，１−ｂ］−１，３，４−チアジアゾール−２−スルホンアミド及びその使用
ES2287786T3 (es) 2003-10-31 2007-12-16 Janssen Pharmaceutica N.V. Derivados de acido fenoxiacetico utiles como agonistas dobles del receptor activado por el proliferador de peroxisomas (ppar).
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
CA2555263A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
EP1867331A4 (en) 2005-04-06 2009-04-08 Takeda Pharmaceutical TRIAZOLE DERIVATIVE AND USE THEREOF
WO2007002540A2 (en) 2005-06-24 2007-01-04 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
EP2001844A2 (en) 2006-03-14 2008-12-17 Amgen, Inc Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
AU2007240082A1 (en) 2006-04-13 2007-10-25 Aegera Therapeutics Inc. Use of imidazo[2,1-b)]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain
DE102006054757A1 (de) 2006-11-21 2008-05-29 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP1964841A1 (en) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
WO2009027733A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
GB0718735D0 (en) 2007-09-25 2007-11-07 Prolysis Ltd Antibacterial agents
EP2231659A4 (en) 2007-12-21 2011-10-26 Univ Sydney TRANSLOKATORPROTEINLIGANDEN
AU2009231906A1 (en) 2008-03-31 2009-10-08 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
CN102159582B (zh) 2008-07-15 2014-05-07 赛诺菲-安万特 作为Edg-1受体激动剂的噁唑并嘧啶
KR101718386B1 (ko) 2008-09-26 2017-03-21 내셔날 헬스 리서치 인스티튜트 단백질 키나아제 억제제로서의 융합 다환 화합물
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
MX2012006994A (es) * 2009-12-18 2012-07-03 Mitsubishi Tanabe Pharma Corp Agente antiplaquetas novedoso.
CN102372701A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 氮杂双环己烷类衍生物、其制备方法及其在医药上的应用
SG187795A1 (en) 2010-08-11 2013-03-28 Millennium Pharm Inc Heteroaryls and uses thereof
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
JP6101343B2 (ja) 2012-04-26 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾールおよびイミダゾピリダジン誘導体
EA201491959A1 (ru) 2012-04-26 2016-05-31 Бристол-Майерс Сквибб Компани Агонистические пептиды для par4
LT2841437T (lt) * 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
WO2013163244A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
ES2624291T3 (es) 2012-04-27 2017-07-13 Novartis Ag Inhibidores cíclicos del enlace éter de DGAT1
MA37519B1 (fr) 2012-05-15 2017-03-31 Novartis Ag Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
TR201808818T4 (tr) 2012-06-21 2018-07-23 Novo Nordisk As Gip reseptör aktivitesi sergileyen glukagon analogları.
AR092348A1 (es) 2012-07-11 2015-04-15 Hoffmann La Roche DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
EP2875029B8 (en) 2012-07-18 2021-12-15 University of Notre Dame du Lac 5,5-heteroaromatic anti-infective compounds
TW201422592A (zh) 2012-08-27 2014-06-16 Boehringer Ingelheim Int β－分泌酶抑制劑
PT2909195T (pt) 2012-10-16 2017-09-13 Janssen Sciences Ireland Uc Compostos antivirais de vsr
PE20151067A1 (es) 2012-12-19 2015-08-05 Novartis Ag Inhibidores de autotaxina
PH12019501848A1 (en) 2012-12-21 2020-03-02 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Also Published As

Publication number Publication date
SMT202000049T1 (it) 2020-03-13
PT3632919T (pt) 2023-01-06
BR112014026643B1 (pt) 2023-03-07
HRP20192336T1 (hr) 2020-03-20
PH12014502173B1 (en) 2021-04-14
ES2770026T3 (es) 2020-06-30
PH12014502173A1 (en) 2014-12-10
US20170247395A1 (en) 2017-08-31
CN108383858A (zh) 2018-08-10
LT2841437T (lt) 2017-09-11
KR20200040308A (ko) 2020-04-17
EP3243826A1 (en) 2017-11-15
PL3632919T3 (pl) 2023-02-20
PT2841437T (pt) 2017-09-28
EP2841437A1 (en) 2015-03-04
EP3243826B1 (en) 2019-10-30
IL235246B (en) 2018-11-29
FI3632919T3 (fi) 2023-01-13
EA201491968A1 (ru) 2015-05-29
SI2841437T1 (sl) 2017-09-29
PE20142285A1 (es) 2015-01-08
SG11201406757SA (en) 2014-11-27
EP3632919B1 (en) 2022-10-26
TN2014000436A1 (en) 2016-03-30
EP3632919A1 (en) 2020-04-08
PT3243826T (pt) 2020-01-28
US20230242535A1 (en) 2023-08-03
HUE034566T2 (hu) 2018-02-28
HK1203953A1 (en) 2015-11-06
EP2841437B1 (en) 2017-07-05
CY1122625T1 (el) 2021-03-12
LT3632919T (lt) 2023-02-27
MY175061A (en) 2020-06-04
AU2013251632A1 (en) 2014-11-13
DK3632919T3 (da) 2022-11-14
RS59882B1 (sr) 2020-03-31
US20250002497A1 (en) 2025-01-02
AR090834A1 (es) 2014-12-10
HUE048654T2 (hu) 2020-08-28
BR112014026643A8 (pt) 2021-06-15
DK3243826T3 (da) 2020-02-03
US10822343B2 (en) 2020-11-03
NZ631027A (en) 2016-03-31
JP6073464B2 (ja) 2017-02-01
HUE060743T2 (hu) 2023-04-28
KR102098804B1 (ko) 2020-04-08
AU2013251632B2 (en) 2016-12-15
ES2640916T3 (es) 2017-11-07
HRP20221495T1 (hr) 2023-02-03
DK2841437T3 (en) 2017-10-23
US20180305376A1 (en) 2018-10-25
JP2015514808A (ja) 2015-05-21
RS63975B1 (sr) 2023-03-31
MX2014012296A (es) 2015-01-14
RS56395B1 (sr) 2017-12-29
CN104583218A (zh) 2015-04-29
CL2014002915A1 (es) 2015-02-13
SI3632919T1 (sl) 2023-02-28
US20150094297A1 (en) 2015-04-02
US10047103B2 (en) 2018-08-14
SI3243826T1 (sl) 2020-03-31
UY34763A (es) 2013-10-31
EA026724B1 (ru) 2017-05-31
CA2871650A1 (en) 2013-10-31
CN104583218B (zh) 2018-04-24
TW201350487A (zh) 2013-12-16
SMT202300004T1 (it) 2023-03-17
US12084452B2 (en) 2024-09-10
TWI572605B (zh) 2017-03-01
CO7160040A2 (es) 2015-01-15
MX354175B (es) 2018-02-16
CA2871650C (en) 2017-09-19
KR102176379B1 (ko) 2020-11-09
ES2935173T3 (es) 2023-03-02
PL2841437T3 (pl) 2017-12-29
BR112014026643A2 (pt) 2017-06-27
KR20150009532A (ko) 2015-01-26
KR20200127273A (ko) 2020-11-10
SMT201700457T1 (it) 2017-11-15
CY1119466T1 (el) 2018-03-07
WO2013163279A1 (en) 2013-10-31
PL3243826T3 (pl) 2020-08-24
HRP20171453T1 (hr) 2017-11-17
US10428077B2 (en) 2019-10-01
US9688695B2 (en) 2017-06-27
CN108383858B (zh) 2024-09-20
US20200123160A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
ZA201407799B (en) Imidazothiadiazole an imidazopyrazine derivatives as protease activated receptor 2(par4) inhibitors for treating platelet aggregation
IL235140A0 (en) Imidazothiadiazole derivatives as protease-activated receptor 4 (par4) inhibitors for the treatment of platelet aggregation
IL235141A0 (en) Imidazothiadiazole and imidazopyridazine derivatives as protease-activated receptor 4 (par4) inhibitors for the treatment of platelet aggregation
ZA202001242B (en) Tricyclic heterocycles as bet protein inhibitors
IL237475A0 (en) Pyrlotriazinone derivatives as pi3k inhibitors
HUE051078T2 (hu) 4-karboxamido-izoindolinone származék mint szelektív parp-1 inhibitor
AP2015008236A0 (en) Azaindole derivatives which acht as PI3K inhibitors
SI2912041T1 (sl) Derivati tetrahidropirolotiazina kot inhibitorji beta sekretaze (bace)
ZA201405227B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
ZA201508968B (en) Imidazo-triazine derivatives as pde10 inhibitors
PL2830980T3 (pl) Urządzenie do wytwarzania opakowań zbiorczych